BRPI0515918A8 - sais de composto heterocíclico de ligação à quimiocina e métodos para seu uso - Google Patents

sais de composto heterocíclico de ligação à quimiocina e métodos para seu uso Download PDF

Info

Publication number
BRPI0515918A8
BRPI0515918A8 BRPI0515918A BRPI0515918A BRPI0515918A8 BR PI0515918 A8 BRPI0515918 A8 BR PI0515918A8 BR PI0515918 A BRPI0515918 A BR PI0515918A BR PI0515918 A BRPI0515918 A BR PI0515918A BR PI0515918 A8 BRPI0515918 A8 BR PI0515918A8
Authority
BR
Brazil
Prior art keywords
methods
chemokine
heterocyclic compound
compound salts
binding
Prior art date
Application number
BRPI0515918A
Other languages
English (en)
Inventor
Chen Gang
R Baird Ian
B Crawford Jason
Skerlj Renato
Zhu Yongbao
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of BRPI0515918A publication Critical patent/BRPI0515918A/pt
Publication of BRPI0515918A8 publication Critical patent/BRPI0515918A8/pt
Publication of BRPI0515918B1 publication Critical patent/BRPI0515918B1/pt
Publication of BRPI0515918B8 publication Critical patent/BRPI0515918B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"sais de composto heterocíclico de ligação à quimiocina e métodos para seu uso". a presente invenção refere-se a sais de composto heterocíclico de ligação à quimiocina, métodos para seu uso e métodos para preparação dos mesmos.
BRPI0515918A 2004-09-29 2005-09-26 sais de composto heterocíclico de ligação à quimiocina, seu processo de preparação e composição farmacêutica que os compreende BRPI0515918B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61479004P 2004-09-29 2004-09-29
US60/614,790 2004-09-29
PCT/US2005/034491 WO2006039250A2 (en) 2004-09-29 2005-09-26 Chemokine-binding heterocyclic compound salts, and methods of use thereof

Publications (4)

Publication Number Publication Date
BRPI0515918A BRPI0515918A (pt) 2008-08-12
BRPI0515918A8 true BRPI0515918A8 (pt) 2020-02-11
BRPI0515918B1 BRPI0515918B1 (pt) 2021-04-13
BRPI0515918B8 BRPI0515918B8 (pt) 2021-05-25

Family

ID=36142992

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515918A BRPI0515918B8 (pt) 2004-09-29 2005-09-26 sais de composto heterocíclico de ligação à quimiocina, seu processo de preparação e composição farmacêutica que os compreende

Country Status (10)

Country Link
US (1) US7723525B2 (pt)
EP (1) EP1799215B1 (pt)
JP (1) JP5209314B2 (pt)
CN (1) CN101111249B (pt)
BR (1) BRPI0515918B8 (pt)
CA (1) CA2582911C (pt)
ES (1) ES2581559T3 (pt)
MX (1) MX2007003861A (pt)
TW (1) TW200619206A (pt)
WO (1) WO2006039250A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
JP5245827B2 (ja) 2006-07-31 2013-07-24 小野薬品工業株式会社 スピロ結合した環状基を含有する化合物およびその用途
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017106328A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法
WO2017216373A1 (en) * 2016-06-16 2017-12-21 Centre National De La Recherche Scientifique Cxcr4 receptor-binding compounds useful for increasing interferon level
CN109562106B (zh) 2016-06-21 2023-03-21 X4 制药有限公司 Cxcr4抑制剂及其用途
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US20220017487A1 (en) * 2020-07-16 2022-01-20 X4 Pharmaceuticals, Inc. Deuterated compounds and uses thereof
EP4085910A1 (en) * 2021-05-05 2022-11-09 4Living Biotech Use of a compound such as plerixafor for treating a viral pulmonary disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
BR9815377A (pt) * 1997-09-30 2001-01-16 Daiichi Pharmaceutical Co Ltda Derivados de sulfonil
AU2001252350A1 (en) * 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
CA2419310A1 (en) * 2000-08-23 2002-02-28 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
RU2289581C2 (ru) * 2000-09-15 2006-12-20 Анормед, Инк. Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение
NZ524421A (en) * 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
JP2004512336A (ja) * 2000-09-15 2004-04-22 アノーメッド　インコーポレイティド ケモカインレセプター結合複素環式化合物
DE10161963A1 (de) * 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
MXPA04006136A (es) 2001-12-21 2004-11-01 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DOP2003000556A (es) * 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
SI1482924T1 (sl) * 2002-03-05 2008-12-31 Merck Frosst Canada Ltd Katepsin cistein proteazni inhibitorji
EP1724263B1 (en) * 2004-03-10 2014-03-05 Kureha Corporation Basic amine compound and use thereof
ES2614508T3 (es) * 2004-03-15 2017-05-31 Genzyme Corporation Proceso para la síntesis de un antagonista de CXCR4

Also Published As

Publication number Publication date
ES2581559T3 (es) 2016-09-06
EP1799215A4 (en) 2010-08-18
WO2006039250A3 (en) 2006-10-19
EP1799215B1 (en) 2016-06-01
US20060069122A1 (en) 2006-03-30
JP2008514708A (ja) 2008-05-08
JP5209314B2 (ja) 2013-06-12
CN101111249A (zh) 2008-01-23
TW200619206A (en) 2006-06-16
EP1799215A2 (en) 2007-06-27
CA2582911C (en) 2013-12-10
BRPI0515918B1 (pt) 2021-04-13
MX2007003861A (es) 2008-02-19
CA2582911A1 (en) 2006-04-13
US7723525B2 (en) 2010-05-25
CN101111249B (zh) 2011-01-19
BRPI0515918A (pt) 2008-08-12
BRPI0515918B8 (pt) 2021-05-25
WO2006039250A2 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
BRPI0515918A8 (pt) sais de composto heterocíclico de ligação à quimiocina e métodos para seu uso
CY1108393T1 (el) Αναστολεις διπεπτιδυλ πεπτιδασης
LTPA2018501I1 (lt) Heterocikliniai amido dariniai, naudingi kaip mikrobiocidai
BRPI0514372A (pt) inibidores de tiazol de frutose 1, 6-bisfosfatase
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
NO20071880L (no) Diagnostic Compounds
WO2007048065A3 (en) Pyrimidinones as casein kinase ii (ck2) modulators
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
DK1764127T3 (da) Nålebeskyttelsesklemme med hæl
BRPI0812877A2 (pt) " compostos de piperazina, uso de um composto de piperazina, composição, e, método para combater vegetação indesejada ".
BRPI0813683A2 (pt) composto amina e uso farmacêutico do mesmo
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
BRPI0822033A2 (pt) Composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, kit
HK1133012A1 (en) Pyrimidinones as casein kinase ii (ck2) modulators
BRPI0614730A2 (pt) composto, composição farmacêutica, e, uso de um composto
DK1910270T3 (da) For PPAR-receptorer og EGF-receptorer specifikke forbindelser og deres salte samt deres anvendelse på det medicinske område
BRPI0814208A2 (pt) Composição para conferir agentes de benefício a substratos aniônicos, e métodos para seu uso.
BRPI0600127A (pt) pigmentos de ferrita de zinco estáveis à redução, processo para produção dos mesmos e seu uso
BRPI0514452A (pt) composições, métodos de fabricação e uso de compostos de guanilhidrazona
DE502005000568D1 (de) Feste Zubereitungen enthaltend Ammoniumnitril
BRPI0511819A (pt) sais de guanilidrazona, composições, processos de fabricação e métodos de uso
BRPI0612270A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0414732A (pt) piridilacetilenos para uso como radiotraçadores e agentes de imageamento
BRPI0606146A2 (pt) compostos de sais fosfato 6-dimetilaminometil-1-(3-metoxifenil)-1,3-dihidroxicicl ohexano
BRPI0823049A2 (pt) Anticorpos para glicoesfingolipídeos tipo 1 anti-estendidos, derivados dos mesmos e uso.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled

Free format text: REFERENTE A RPI NO 2051 DE 27/04/2010.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.1 NA RPI NO 2580 DE 16/06/2020 POR TER SIDO INDEVIDA.

B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/09/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF